Trial
NCT03028987
Adaptive Immune Responses and Repertoire in Influenza Vaccination and Infection (SLVP031)
Phase IVTERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Stanford University
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
Condition
Influenza
Intervention
Fluzone®
Why stopped
LAIV was no longer recommended by ACIP
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-09-12